HRT Financial’s Enanta Pharmaceuticals ENTA Stock Holding History

HRT Financial’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-33,188	Closed	-$397K	–	3375
2025 Q3	$397K	Buy	+33,188	New	+$265K	﹤0.01%	2010
2023 Q4	–	Sell	-102,698	Closed	-$1.15M	–	2503
2023 Q3	$1.15M	Buy	+102,698	New	+$1.65M	0.01%	894
2023 Q2	–	Sell	-10,425	Closed	-$421K	–	2663
2023 Q1	$421K	Buy	+10,425	New	+$498K	0.01%	1501
2022 Q4	–	Sell	-18,673	Closed	-$968K	–	2634
2022 Q3	$968K	Buy	+18,673	New	+$1.09M	0.01%	954
2022 Q1	–	Sell	-6,295	Closed	-$470K	–	3285
2021 Q4	$470K	Buy	6,295 +330	+6%	+$25.9K	﹤0.01%	1940
2021 Q3	$338K	Sell	5,965 -9,865	-62%	-$488K	﹤0.01%	2330
2021 Q2	$696K	Buy	+15,830	New	+$775K	0.01%	1486
2019 Q4	–	Sell	-3,739	Closed	-$224K	–	1278
2019 Q3	$224K	Buy	+3,739	New	+$278K	0.01%	1093

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HRT Financial's ENTA Position: Q4 2025 in Review

HRT Financial sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 33,188 shares — an estimated $397K sold.

HRT Financial first reported a position in ENTA in Q3 2019 and held it in 8 quarters. The position peaked at $1.15M in Q3 2023. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

HRT Financial reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
HRT Financial sold 33,188 Enanta Pharmaceuticals shares in Q4 2025, an estimated $397K.
HRT Financial first reported a position in Enanta Pharmaceuticals in Q3 2019 and held it in 8 quarters.
HRT Financial's Enanta Pharmaceuticals position peaked at $1.15M in Q3 2023.
131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.